# Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

> **NCT02970981** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 18 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT02970981
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-29
- **Primary completion:** 2018-11
- **Final completion:** 2022-05-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970981, "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02970981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*